THE IRVING AREA OF TEXAS, DECEMBER. 4, 2023 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI, today announced that the company and collaborators within the Caris Precision Oncology Alliance™ (POA) will collectively present findings at the San Antonio Breast Cancer Symposium (SABCS) that illustrate the potential impact of molecular profiling on the treatment of breast cancer. These findings demonstrate the power of Caris' comprehensive clinico-genomic database that enables new insights into cancer that could have profound effects on a patient's cancer diagnosis, prognosis, treatment plan, and response to treatment in the future. There will be a SABCS conference held from December 5-9, 2023 (Booth #1433) in San Antonio, Texas.
There will be a SABCS conference held from December 5-9, 2023 (Booth #1433) in San Antonio, Texas.
According to George W. Sledge, Jr., MD, Executive Vice President and Chief Medical Officer of Caris, the San Antonio Breast Cancer Symposium has established itself as the premier breast cancer research conference. As part of our continuing commitment to the breast cancer community, Caris is proud to share important clinical and translational research that Caris has collaborated with academic partners on important breast cancer questions.
I am pleased to confirm that the San Antonio Breast Cancer Symposium continues to be one of the leading conferences for breast cancer research," said George W. Sledge, Jr., MD, Executive Vice President and Chief Medical Officer at Caris. As part of our continuing commitment to the breast cancer community, Caris is proud to share important clinical/translational research we have conducted with our academic partners on important breast cancer questions.
As a result of the research findings, Caris' comprehensive clinico-genomic database has been shown to be powerful 
The following are some of the presentations and posters that Caris has made:
Dr. Milan Radovich, Senior Vice President and Chief Scientific Officer of Caris, will participate in a concurrent Educational Session entitled "Genomics for Clinical Research and Cancer Care" from 3:10 p.m. to 5:00 p.m.. CT on Thursday, December 7 at 2:00 p.m. in the Stars at Night Ballrooms 1 and 2. The Dr.. The topic of Radovich's presentation will be "Emerging approaches to targeting pathways using precision medicine in breast cancer," which is scheduled for 3:10 p.m. to 3:40 p.m.. Before taking part in a panel discussion from 4:40 p.m. to 5:00 p.m..There has been a rapid evolution in precision oncology in breast cancer with the recent approval of several targeted therapies that rely on the detection of molecular biomarkers to inform the selection of treatment. Several novel genomic and artificial intelligence-based approaches are on the horizon that will further shape the future treatment of this disease, said Dr. Zhu.. Radovich, Igor. The educational session that will take place at SABCS will address advances in new drug modalities and targetable pathways, liquid biopsies, and clonal hematopoiesis, emerging evidence about treatment resistance, and the cutting edge of AI-enabled digital pathology for biomarker detection..The Caris study will be featured in the Concurrent Poster Spotlight Sessions Block 5 in the "PS13 Special Populations: Pregnancy, Male, and Geriatric Patients" section at 5:30 - 6:30 pm on Thursday, December 7 during the Concurrent Poster Spotlight Sessions.. CT in the Stars at Night Ballrooms 3 and 4. There will be a spotlight poster entitled "Molecular and Immunological Landscape of Sex-Based Differences in Breast Cancer: A Distinct Disease in Men" (Presentation #PS13-09) at the meeting.. Caris Precision Oncology AllianceTM (POA) members Dana-Farber Cancer Institute and Legorreta Cancer Center at Brown University, along with the Mayo Clinic, conducted the study in collaboration with the Caris Precision Oncology AllianceTM (POA) members.. In the featured study, Caris' Next-Generation Sequencing (NGS) technology was used to study the molecular and immunological landscapes of male and female breast cancer by analyzing 10,728 samples of breast cancer (male, n=137, female, n=10,591) using Caris' Next-Generation Sequencing (NGS) platform.. According to the results of this analysis, male breast cancer exhibits a number of different molecular and immune characteristics in comparison with female breast cancer. By better understanding these sex-based differences, we may be able to make better decisions about disease outcomes, provide a rationale for tailoring therapeutic approaches, and design future treatments in a more effective manner.The Caris Precision Oncology AllianceTM continues to make significant contributions to the advancement of breast cancer research by presenting new findings at this year's SABCS on molecular and immunological features of the male breast cancer," said Chadi Nabhan, MD, MBA, FACP, Chairman of the Caris Precision Oncology AllianceTM.. "By leveraging Caris' extensive real-world clinico-genomic database, our academic partners are able to uncover new insights into the underpinnings of breast cancer biology, which will allow them to develop better therapeutic interventions for the fight against breast cancer.".As part of the POA, 90 cancer centers, academic institutions, research consortia, and healthcare systems, including 42 NCI-designated cancer centers, are collaborating to advance precision oncology and biomarker-driven research in cancer.. Through innovative research that focuses on identifying predictive and prognostic markers that improve the clinical outcomes for cancer patients, the POA member organizations work together to establish and optimize standards of care for molecular testing.There will be additional presentations from Carlis demonstrating the potential impact of comprehensive molecular profiling in the treatment of breast cancer in addition to the existing data from studies demonstrating the critical role of precision medicine and molecular profiling in the treatment of breast cancer.. In the beginning of December, all presentations will be made available to the public on Caris' website. Comprehensive Molecular and Immunological Characterization of Invasive Ductal Triple-Negative Breast Cancer (Presentation Number: PO4-24-01) This investigation of the molecular and immune signatures of invasive ductal (ID) triple-negative breast cancer (TNBC) was carried out in order to develop a better understanding of TNBC biology in order to identify new targets that will facilitate future treatments for this heterogeneous disease.. In this retrospective study of more than 13,000 breast cancer samples, it was determined that ID TNBC was associated with a distinct mutational profile as well as an immunological profile compared to ID non-TNBC. As a result, ID TNBC is also associated with a worse overall survival when compared to ID non-TNBC. It should be noted, however, that ID TNBC patients have improved survival as a result of pembrolizumab treatment. The purpose of this study was to investigate the expression of genes from the BCL2 family in metaplastic triple-negative breast cancer (Presentation Number: PO4-24-02) This study aimed to investigate the expression of genes from the BCL2 family in metastatic TNBC. According to the findings of this molecular profiling study, there is a strong correlation between higher levels of PMAIP1 expression and a poorer prognosis for patients with this type of cancer. A possible explanation for this association may be due to a higher expression of immune checkpoint and stem cell-related genes in PMAIP1-positive tumors, as well as a higher frequency of PD-L1 positivity among these tumors. In order to prospectively validate PMAIP1 as a potential prognostic biomarker candidate in metaplastic TNBC, more investigation is required. It has been shown that the genomic landscape of malignant Phyllodes tumors can be used to identify subsets for targeted therapy (Presentation Number: PO4-24-08) Phyllodes tumors are rare tumors of the breast, with a subset having substantial malignancy potential. The purpose of this study was to identify targetable alterations and improve understanding of the mutational profiles of malignant phyllodes tumors (MPTs) in order to possibly enhance treatment options in the future. An NGS analysis identified actionable genomic alterations, including an NTRK1 fusion and a low expression of the transcription factor HER2. It is clear from these results that NGS-based profiling, including RNA sequencing, has a significant role to play in MPT research in order to uncover potential targeted treatment options for patients with MPT. About Caris Life SciencesCaris Life Sciences® (Caris) is the leading next-generation AI TechBio company and precision medicine pioneer. Our company is actively developing and delivering innovative solutions that are revolutionizing healthcare and improving the human condition with the use of molecular science and artificial intelligence.. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced AI and machine learning algorithms, Caris has created the large-scale, clinico-genomic database and computing capabilities needed to analyze and unravel the molecular complexity of disease through the application of advanced artificial intelligence and machine learning algorithms.. The convergence of sequencing power, big data, and artificial intelligence technologies is providing a platform that is unmatched in its ability to provide the next generation of precision medicine tools for early detection, diagnosis, monitoring, therapy selection, and the development of new drugs..Caris is headquartered in Irving, Texas and also has offices in Phoenix, New York, Tokyo, Japan, and Basel, Switzerland.. In the U.S., Caris or its distributor partners provide a range of services.Markets in North America, Europe, Asia, and other international markets. You can learn more about CarisLifeSciences by visiting their website.Please visit www.com.Media Contact for Caris Life Sciences is Lisa Burgner at [email protected]2114.I am 294..The 5606SOURCE is Caris Life Sciences
The 5606SOURCE is Caris Life Sciences
In the featured study, Caris' Next-Generation Sequencing (NGS) technology was used in order to investigate the molecular and immunological landscapes of male and female breast cancer over a large sample size of 10,728 breast cancer samples (male, n = 137; female, n = 10,591).. The results of this study indicate that there are differences between the molecular and immune features of male breast cancers and those of female breast cancers based on the results of this study. As we gain a deeper understanding of these sex-based differences, we may be able to better inform disease outcomes, provide a rationale for tailored therapeutic approaches, and guide the design of future treatments applicable to these conditions
As we gain a deeper understanding of these sex-based differences, we may be able to better inform disease outcomes, provide a rationale for tailored therapeutic approaches, and guide the design of future treatments applicable to these conditions
It is our pleasure to again contribute to the advancement of breast cancer research as the Caris Precision Oncology AllianceTM presents novel findings on both the molecular and immunological features of male breast cancer at this year's SABCS," says Chadi Nabhan, MD, MBA, FACP, Chairman of the POA.. Using Caris' extensive real-world clinico-genomic database, our academic partner institutions will be able to gain new insights into the molecular underpinnings of breast cancer biology, in turn leading to better therapeutic approaches for the treatment of this disease
 Using Caris' extensive real-world clinico-genomic database, our academic partner institutions will be able to gain new insights into the molecular underpinnings of breast cancer biology, in turn leading to better therapeutic approaches for the treatment of this disease
With a goal to advance precision oncology and biomarker-driven research, the POA is a collaboration between 90 cancer centers, academic institutions, research consortia, and healthcare systems, including 42 cancer centers designated by the National Cancer Institute. In order to improve the clinical outcomes of cancer patients, POA members work together to set and optimize standards of care for molecular testing by conducting innovative research on predictive and prognostic markers.
The results of additional presentations provide insight into the potential impact of comprehensive molecular profiling
On December 7, Caris will present more data from studies that demonstrate the critical role of precision medicine and molecular profiling in the treatment of breast cancer. All presentations will be available online through Caris' website from the beginning of December.
Introducing Caris Life Sciences (Caris Life Sciences®)Caris Life Sciences® (Caris) is the leading next-generation AI TechBio company and a precision medicine pioneer that is developing and delivering innovative solutions based on molecular science and artificial intelligence that will revolutionize healthcare and improve the human condition.. It has been Caris' goal to create a large, clinico-genomic database and computing capability that allows for the analysis and unraveling of disease molecular complexity through comprehensive molecular profiling (Whole Exome Sequencing and Whole Transcriptome Sequencing) and the use of advanced artificial intelligence and machine learning algorithms.. As a result of this convergence of sequencing power, big data, and artificial intelligence technologies, we can now deliver a next-generation of precision medicine tools which can be used for early detection, diagnosis, monitoring, treatment choice, and drug development in the future.
As a result of this convergence of sequencing power, big data, and artificial intelligence technologies, we can now deliver a next-generation of precision medicine tools which can be used for early detection, diagnosis, monitoring, treatment choice, and drug development in the future.
As well as its headquarters in Irving, Texas, Caris has offices in Phoenix, New York, Tokyo, Japan, Basel, Switzerland, and other international locations. Caris, or its distributor partners, provide services in the U.S., Europe, Asia, and other countries around the world. To learn more, visit CarisLifeSciences.com.
Media Contact for Caris Life Sciences: Lisa Burgner[email protected] 214.294.5606
Caris Life Sciences is the source of this information
Founded in 2004, Caris Life Sciences® (Caris) is one of the leaders in next-generation AI Biotech companies and a precision medicine pioneer in the region, actively developing and delivering ...
It is with great pleasure that I welcome you to Caris Life Sciences® (Caris), a leading next-generation AI TechBio company and an Industry pioneer in precision medicine that is actively developing and delivering...
We'll deliver PRN's top stories and curated news straight to your inbox every week if you sign up!

Source prnewswire